BeOne Medicines (BEIGF) Net Cash Flow (2015 - 2026)

BeOne Medicines (BEIGF) has reported Net Cash Flow for 12 consecutive years, with $407.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 75.6% year-over-year to $407.4 million in Q2 2026; TTM through Jun 2026 was $2.4 billion, a 1372.0% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 485.62% from the prior year.
• Net Cash Flow was $407.4 million for Q2 2026 at BeOne Medicines, up from $224.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.3 billion in Q3 2025 and troughed at -$390.0 million in Q4 2022.
• A 5-year average of $51.5 million and a median of -$30.2 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 815.09% in 2023 and jumped 2172.2% in 2025, its largest moves.
• Over 5 years, Net Cash Flow stood at -$390.0 million in 2022, then jumped by 116.11% to $62.8 million in 2023, then sank by 136.56% to -$23.0 million in 2024, then jumped by 2172.2% to $475.9 million in 2025, then fell by 14.4% to $407.4 million in 2026.
• The last three Net Cash Flow figures came in at $407.4 million (Q2 2026), $224.5 million (Q1 2026), and $475.9 million (Q4 2025), per Business Quant data.